Sarepta Therapeutics (Nasdaq: SRPT) has announced it will cease development of SRP-5051, an experimental drug for Duchenne ...

JPMorgan sees a long-term buying opportunity after Sarepta (SRPT) shares were under pressure last week post earnings. Near-term, if one ...

including myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne muscular dystrophy (DMD). In DM1, Avidity Biosciences continues to progress with their Phase 3 ...

Neurotech has appointed Dr Anthony Filippis as its managing director to steer the company as it progresses clinical testing ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

Santhera has completed a rolling application for its Duchenne muscular dystrophy (DMD) therapy vamorolone in the US, setting up a possible approval and launch in the latter half of 2023. The Swiss ...

The company has shown promising results in its preclinical and early clinical trials, particularly with its lead program ...

The Dogs for the Disabled charity has secured a brand new premises in Cork - which will slash waiting times for people in ...

Saudi researchers from Qassim University identified Bethlem Myopathy, a rare genetic disorder. The scientific discovery sheds ...

Amit Shah vows anti-conversion law in Maharashtra, opposition caste census Union Home Minister Amit Shah, during the release of BJP's election manifesto in Mumbai, promised a stringent anti ...

People drink takeaway coffee in view of the City of London skyline in London, Britain, July 25, 2024. REUTERS/Hollie Adams/File Photo British public-sector employers now expect to raise pay faster ...